Fibrin-based scaffold incorporating VEGF- and bFGF-loaded nanoparticles stimulates wound healing in diabetic mice

Acta Biomaterialia

Volumn 9, Issue 8, 2013, Pages 7814-7821

  Losi, Paola ^a   Briganti, Enrica ^a   Errico, Cesare ^b   Lisella, Antonella ^b   Sanguinetti, Elena ^a   Chiellini, Federica ^b   Soldani, Giorgio ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

BFGF; Fibrin based scaffold; PLGA nanoparticles; VEGF; Wound healing

Indexed keywords

CELL CULTURE; CELL ENGINEERING; CELL PROLIFERATION; DISEASES; ENDOTHELIAL CELLS; MAMMALS; SCAFFOLDS (BIOLOGY); SILICONES; TISSUE REGENERATION;

BASIC FIBROBLAST GROWTH FACTOR; BFGF; DIABETIC MICE; FIBRIN-BASED SCAFFOLDS; GROWTH FACTOR; POLY LACTIC-CO-GLYCOLIC ACID; POLY(LACTIC-CO-GLYCOLIC ACID); POLY(LACTIC-CO-GLYCOLIC ACID) NANOPARTICLE; VASCULAR ENDOTHELIAL GROWTH FACTOR; WOUND HEALING;

NANOPARTICLES;

COLLAGEN; DIMETICONE; FIBRIN; FIBROBLAST GROWTH FACTOR 2; MOLECULAR SCAFFOLD; NANOPARTICLE; POLYETHERURETHAN; POLYGLACTIN; POLYURETHAN; RECOMBINANT VASCULOTROPIN; TISSUE SCAFFOLD; VASCULOTROPIN A; DELAYED RELEASE FORMULATION; DRUG COMBINATION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC FOOT; EPITHELIZATION; GRANULATION TISSUE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NANOENCAPSULATION; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SKIN INJURY; SKINFOLD THICKNESS; WOUND CLOSURE; WOUND DRESSING; WOUND HEALING; ZETA POTENTIAL; ANIMAL; BANDAGE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG COMBINATION; DRUG EFFECT; MATERIALS TESTING; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TREATMENT OUTCOME; ADMINISTRATION AND DOSAGE; DRUG EFFECTS; TISSUE SCAFFOLD;

MUS;

ANIMALS; BANDAGES; DELAYED-ACTION PREPARATIONS; DIABETIC FOOT; DRUG COMBINATIONS; FIBRIN; FIBROBLAST GROWTH FACTOR 2; MALE; MATERIALS TESTING; MICE; MICE, TRANSGENIC; TISSUE SCAFFOLDS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84891689096     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2013.04.019     Document Type: Article

References (35)

1. Goldman R. Growth factors and chronic wound healing: past, present and future. Adv Skin Wound Care 2004;17:24-35.
2. Blakytny R, Jude E. The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med 2006;23:594-608.
3. Li J, Chen J, Kirsner R. Pathophysiology of acute wound healing. Clin Dermatol 2007;25:9-18.
4. McGee GS, Davidson JM, Buckley A, Sommer A, Woodward SC, Aquino AM, et al. Recombinant basic fibroblast growth factor accelerates wound healing. J Surg Res 1988;45:145-53.
5. Frank S, Hübner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1995;270:12607-13.
6. Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN, et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci USA 2009;106:13505-10.
7. Lerman OZ, Galiano RD, Armour M, Levine JP, Gurtner GC. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol 2003;162:303-12.
8. Hanft JR, Pollak RA, Barbul A, Van Gils C, Kwon PS, Gray SM, et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. J Wound Care 2008;17:30-2. 34-37.
9. Uchi H, Igarashi A, Urabe K, Koga T, Nakayama J, Kawamori R, et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. Eur J Dermatol 2009;19:461-8.
10. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F, et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999;7:442-52.
11. Chu Y, Yu D, Wang P, Xu J, Li D, Ding M. Nanotechnology promotes the fullthickness diabetic wound healing effect of recombinant human epidermal growth factor in diabetic rats. Wound Repair Regen 2010;18:499-505.
12. Han G, Nguyen LN, Macherla C, Chi Y, Friedman JM, Nosanchuk JD, et al. Nitric oxide-releasing nanoparticles accelerate wound healing by promoting fibroblast migration and collagen deposition. Am J Pathol 2012;180:1465-73.
13. Blecher K, Martinez LR, Tuckman-Vernon C, Nacharaju P, Schairer D, Chouake J, et al. Nitric oxide-releasing nanoparticles accelerate wound healing in NODSCID mice. Nanomedicine 2012;8:1364-71.
14. Briganti E, Spiller D, Mirtelli C, Kull S, Counoupas C, Losi P, et al. A composite fibrin-based scaffold for controlled delivery of bioactive pro-angiogenetic growth factors. J Control Release 2010;142:14-21.
15. Losi P, Briganti E, Magera A, Spiller D, Ristori C, Battolla B, et al. Tissue response to poly(ether)urethane-polydimethylsiloxane-fibrin composite scaffolds for controlled delivery of pro-angiogenic growth factors. Biomaterials 2010;31:5336-44.
16. Santander-Ortega MJ, Csaba N, Gonzalez L, Bastos-Gonzalez D, Ortega-Vinuesa JL, Alonso MJ. Protein-loaded PLGA-PEO blend nanoparticles: encapsulation, release and degradation characteristics. Colloid Polym Sci 2010;288:141-50.
17. Csaba N, González L, Sánchez A, Alonso MJ. Design and characterisation of new nanoparticulate polymer blends for drug delivery. J Biomater Sci Polym Ed 2004;15:1137-51.
18. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 1999;57:171-85.
19. Briganti E, Losi P, Raffi A, Scoccianti M, Munaò A, Soldani G. Silicone based polyurethane materials: a promising biocompatible elastomeric formulation for cardiovascular applications. J Mater Sci Mater Med 2006;17:259-66.
20. Soldani G, Briganti E. A method for producing a device applicable to biological tissues, particularly a patch for treating damaged tissues, and a device obtained by said method. PCT Patent application No. 052343; 2010.
21. D'Angelo I, Garcia Fuentes M, Parajó Y, Welle A, Vántus T, Horváth A. Nanoparticles based on PLGA:poloxamer blends for the delivery of proangiogenic growth factors. Mol Pharm 2010;7:1724-33.
22. American Diabetes Association. Consensus development conference on diabetic foot wound care. 7-8 April 1999, Boston. Mass Adv Wound Care 1999;1999(12):353-61.
23. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
24. Kirchner LM, Meerbaum SO, Gruber BS, Knoll AK, Bulgrin J, Taylor RA, et al. Effects of vascular endothelial growth factor on wound closure rates in the genetically diabetic mouse model. Wound Repair Regen 2003;11: 127-31.
25. Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, Bastidas N, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 2004;164:1935-47.
26. Yang Y, Xia T, Zhi W, Wei L, Weng J, Zhang C, et al. Promotion of skin regeneration in diabetic rats by electrospun core-sheath fibers loaded with basic fibroblast growth factor. Biomaterials 2011;32:4243-54.
27. Obara K, Ishihara M, Ishizuka T, Fujita M, Ozeki Y, Maehara T, et al. Photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2 stimulates wound healing in healing-impaired db/db mice. Biomaterials 2003;24:3437-44.
28. Jazwa A, Kucharzewska P, Leja J, Zagorska A, Sierpniowska A, Stepniewski J, et al. Combined vascular endothelial growth factor-A and fibroblast growth factor 4 gene transfer improves wound healing in diabetic mice. Genet Vaccines Ther 2010;8:6.
29. Chiellini F, Piras AM, Errico C, Chiellini E. Micro/nanostructured polymeric systems for biomedical and pharmaceutical applications. Nanomedicine (Lond) 2008;3:367-93.
30. Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in vivo delivery of drugs and vaccines. J Nanobiotechnol 2011;9:55.
31. Lü JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 2009;9:325-41.
32. Ashikari-Hada S, Hauchi H, Kariya Y, Kimata K. Heparin regulates vascular endothelial growth factor 165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. J Biol Chem 2005;280:31508-15.
33. van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-coglycolic acid) microparticles. Pharm Res 2000;17:1159-67.
34. Zhou W, Zhao M, Zhao Y, Mou Y. A fibrin gel loaded with chitosan nanoparticles for local delivery of rhEGF: preparation and in vitro release studies. J Mater Sci Mater Med 2011;22:1221-30.
35. Chen C, Schultz GS, Bloch M, Edwards PD, Tebes S, Mast BA. Molecular and mechanistic validation of delayed healing rat wounds as a model for human chronic wounds. Wound Repair Regen 1999;7:486-94.